What You Need to Know About Pulmonary Arterial Hypertension: The Role of Primary Care Physicians
|
|
- Rodger Elliott
- 6 years ago
- Views:
Transcription
1 Saturday General Session What You Need to Know About Pulmonary Arterial Hypertension: The Role of Primary Care Physicians Trushil Shah, MD, MS Assistant Professor of Internal Medicine Pulmonary Hypertension Program UT Southwestern Medical Center Dallas, Texas Educational Objectives By the end of this educational activity, participants should be better able to: 1. Describe the pathophysiology of pulmonary arterial hypertension and how early and aggressive treatment is essential for improved patient outcomes. 2. Identify patients for PAH screening and utilize diagnostic approaches for early detection and referral of PAH patients. 3. Discuss the role of primary care providers as part of the interprofessional healthcare team in the long term management of patients with PAH. Speaker Disclosure Dr. Shah has disclosed that he has received research support from Actelion Pharmaceuticals and he is on the advisory board and speaker s bureau for Gilead Sciences. Supporter Disclosure This educational activity is supported by an educational grant from Actelion Pharmaceuticals. It has been planned and produced by Vemco MedEd with Texas Academy of Family Physicians strictly as an accredited continuing medical education activity. 11
2 ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care physicians who can contribute to early detection of disease and who are responsible for the long-term management of patients with PAH. Learning Objectives At the conclusion of the educational activity, the learner should be able to: Describe the pathophysiology of pulmonary arterial hypertension (PAH) and how early and aggressive treatment is essential for improved patient outcomes. Identify patients for PAH screening and utilize diagnostic approaches for early detection and referral of PAH patients. Discuss the role of primary care providers as part of the interprofessional healthcare team in the long-term management of patients with PAH. FACULTY AND DISCLOSURE Pulmonary Hypertension: Definitions Trushil Shah, MD, MS Assistant Professor of Internal Medicine UT Southwestern Medical Center Dallas, TX Dr. Trushil Shah, MD has relevant financial relationships with the following commercial interests: Advisory Board: Gilead Sciences Research Support: Gilead Sciences and Actelion Pharmaceuticals Dr. Shah does not intend to discuss any off-label uses. No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Pulmonary Hypertension: Mean pulmonary arterial pressure (mpap) 25 mm Hg at rest on right heart catheterization (RHC) Pulmonary arterial hypertension (PAH): Mean pulmonary arterial pressure 25 mm Hg PCWP 15 mm Hg PVR >3 Woods units PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance Hoeper MM, et. al. J Am Coll Cardiol. 2013;62(25 Suppl):D WHO Classification of Pulmonary Hypertension (Dana Point) Group 1: Pulmonary Arterial Hypertension Group 2: Pulmonary Hypertension Secondary to Left Heart Disease Group 3: Pulmonary Hypertension Secondary to Lung Disease and/or hypoxia Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Group 5: PH with Unclear Multifactorial Mechanisms Hemolytic disorders Metabolic disorders Sarcoidosis ARS Question What is the most common cause of pulmonary hypertension? 1. Pulmonary arterial hypertension 2. Pulmonary hypertension secondary to left heart disease 3. Pulmonary hypertension secondary to lung disease 4. Chronic thromboembolic pulmonary hypertension Simonneau G, et al. J Am Coll Cardiol. 2013;62(25 Suppl):D
3 Left Heart Disease is Most Common Cause of PH Detected During Echocardiography World Health Organization (WHO) Group 1 PAH Classification of REVEAL (US Registry) Patients at Enrollment PAH, 2.7% Unknown, 15.4% CTEPH, 2.0% Lung disease, Sleep-related hypoventilation, 9.3% Miscellaneous, 2.7% Left heart disease, 67.9% N=936 of 10,314 patients with echo pulmonary artery systolic pressure (PASP) >40 mm Hg. Strange G, et al. Heart. 2012;98: APAH, associated PAH; IPAH, idiopathic PAH; FPAH, familial PAH; PCH, pulmonary capillary hemangiomatosis; PPHN, persistent pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; CVD/CTD, collagen vascular disease/connective tissue disease; CHD, congenital heart disease; HT, hypertension. Frumkin LR. Pharmacol Rev. 2012;64: Patient Case: Nancy 40-year-old female with dyspnea on exertion and chest pressure for 2 months presents to clinic She reports occasional dizziness on exertion and one episode of syncope while walking her dog Admits to taking diet drugs for 2 years in 1990s and lost 40 pounds with this History No past medical history No medications No drug allergies Family History: Father had coronary artery disease at age 70, no other medical history Social history: Drinks a glass of wine occasionally, never smoker, no illicit drug use Physical Exam BP: 100/70, HR: 92, RR: 16, Temp: Normal, Wt.: 135 lb., Ht.: 5 4 JVD ~14 cm Clear lungs. No wheezes or rhonchi. Regular rate and rhythm, normal S1, loud P2, 3/6 holosystolic murmur best heard at left sternal border in 4 th intercostal space Trace pedal edema ARS Question What would you do next? 1. Refer to pulmonary hypertension specialist 2. Right heart catheterization 3. Transthoracic echocardiogram 4. CT pulmonary angiogram JVD, jugular vein distension 2
4 High Index of Suspicion is Key Products Associated with PAH Review of systems should include: Full connective tissue disease review of system Review of use of illicit drugs, smoking and alcohol Family history (familial PAH and connective tissue disease) Sexual history (HIV) DVT/PE/miscarriages (CTEPH) Congenital heart disease Anemia/hematological disorders/splenectomy Lung disease Galiè N, et al. Eur Respir J. 2016;37: Presenting Symptoms in 2733 Patients in REVEAL Registry Clues to Diagnosis Dyspnea on exertion Fatigue Edema Chest pain/discomfort Presyncope/syncope Dizziness/lightheadedness Cough Palpitations Dyspnea at rest Raynaud's phenomenon EKG, Chest x-ray, PFTs, CT pulmonary angiogram, etc. may be available and can give important clues to diagnosis Follow your usual work-up for dyspnea on exertion Always use available data Percentage Brown LM, et. al. Chest. 2011;140: PFTs, pulmonary function tests EKG Findings in PH Radiographic Findings in PAH Right axis deviation Right ventricular hypertrophy Right atrial enlargement Repolarization abnormality 3
5 CT Findings in PAH CT Findings in PAH Pulmonary Function Tests Mild restriction is common Mild decrease in DLCO If severe restriction or reduction in DLCO, then likely has concomitant ILD (especially with scleroderma patients) or PVOD Nancy s Transthoracic Echocardiogram DLCO, diffusing capacity of the lungs for carbon monoxide; ILD, interstitial lung disease; PVOD, pulmonary veno-occlusive disease Dilated Right Ventricle: RV is larger than LV Septal Flattening Right Atrial enlargement 4
6 PASP is Estimated Using Tricuspid Regurgitant Jet Velocity Echocardiography PASP=RVSP in the absence of pulmonic outflow obstruction Modified Bernoulli Equation RVSP= 4(V TR ) 2 + RAP PASP, pulmonary artery systolic pressure; RVSP, right ventricle systolic pressure; RAP, right atrial pressure Barnett C, et al. JAMA. 2008;299: Galiè N, et al. Eur Respir J. 2016;37: Echocardiographic Signs Used to Assess the Probability of PH (in Addition to Tricuspid Regurgitation Velocity) ARS Question What should we do next? 1. Start sildenafil 2. Start ambrisentan 3. Obtain VQ scan 4. Obtain pulmonary function test Galiè N, et al. Eur Respir J. 2016;37: VQ, ventilation-perfusion VQ Scan Significant number of patients with CTEPH do not have a prior history of PE/DVT CTEPH is the only form of PH that is treatable with surgery (i.e., pulmonary endarterectomy) Mortality from pulmonary endarterectomy <5% at expert centers Nancy s VQ scan 5
7 ARS Question Abnormal VQ scan in a patient with CTEPH What next? 1. Pulmonary angiogram 2. Right heart catheterization 3. Start sildenafil 4. Start macitentan Assessment of Pressures as the Catheter Passes Through the Heart Pulmonary Hemodynamics in Different Groups of Pulmonary Hypertension Left heart disease: High PCWP and normal PVR VC RA RV PA PV LA LV PC Aorta Normal PCWP ( 15 mm Hg) and High PVR Pulmonary Arterial Hypertension PH secondary to lung disease CTEPH Murray & Nadel s Textbook of Respiratory Medicine, 6 th ed, Elsevier PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; VC, vena cava; RA, right atrium; RV, right ventricle; PA, pulmonary artery; PC, pulmonary capillaries; PV, pulmonary veins; LA, left atrium; LV, left ventricle 2015 ESC/ERS Diagnostic Algorithm Galiè N, et al. Eur Respir J. 2016;37:
8 PAH Medication Targets 2015 ESC/ERS Recommendations for Monotherapy for PAH (Group 1) Galiè N, et al. Eur Respir J. 2016;37: Why is it Important to Know About This Disease and Recognize it Early? Modern PAH Therapy has Reduced Mortality from this Disease Significantly Median time to diagnosis of PAH from symptom onset by RHC in 1980s was 1.3 years In 2000 s median time to diagnosis of PAH from symptom onset is still 1.1 years Rich S, et al. Ann Intern Med. 1987;107: Badesch DB, et al. Chest. 2010;137: Benza RL, et al. Chest. 2012;142: Factors That Play a Role in Delay in Diagnosis Role of Primary Care Physician Obstructive airway disease (OR 1.93) Obstructive sleep apnea (OR 1.72) Age <36 years (OR 3.07) Six-minute walk distance <250 meters (OR 1.91) Identify PAH early Refer to expert PAH center early for management Help co-manage co-existing conditions or underlying conditions Help co-manage drug side effects Be aware of drug interactions with pulmonary vasodilators Help with diuretic management Counsel patient regarding contraception and avoiding pregnancy Brown LM, et al. Chest. 2011;140:
9 Management of Associated Conditions Common Side Effects Connective tissue diseases (CTDs) like SLE, scleroderma, rheumatoid arthritis and myositis Anticoagulation management Though, to date, no immunosuppressive therapy has been proven to be effective for PAH in CTD-associated PAH, flares of these conditions need to be promptly identified and treated SLE, systemic lupus erythematosus PDE-5 inhibitors Nose bleeds Headache Dyspepsia Flushing Visual disturbances Diarrhea Endothelin Receptor Antagonists Peripheral edema Flushing Headache Dyspepsia Anemia Nasal congestion Elevated liver enzymes (esp. bosentan) Prostaglandins and Prostanoids Nausea, vomiting Flushing Jaw pain Headache Myalgia Hyperthyroidism (selexipag) Diarrhea Skin rash ARS Question Drug Safety and Interactions Which medication is contraindicated in patients on PDE-5 inhibitor therapy? 1. Azithromycin 2. Levofloxacin 3. Aspirin 4. Sublingual nitroglycerin PDE-5 inhibitors Avoid nitrates: can cause lifethreatening hypotension Avoid use with riociguat Protease inhibitors Endothelin receptor antagonists Teratogenic Prostaglandins Selexipag should not be used with gemfibrozil Avoiding Pregnancy Patients with pulmonary hypertension do not tolerate physiological changes in pregnancy like increased plasma volume, increased cardiac output, and decreased systemic vascular resistance (SVR) well and often decompensate Preventing Pregnancy in PAH Advise patients to use at least 2 methods of contraception (generally IUD/progesterone implant/depot + condoms) Endothelin receptor antagonist and riociguat are teratogenic and pregnancy category X Selexipag is pregnancy category B1 and should be avoided Pieper PG, et al. Best Pract Res Clin Obstet Gynaecol. 2014;28:
10 Communication with PAH Specialists Diuretic management Cardio-renal syndrome (oftentimes, BMPs will have elevated creatinine) Worsening of symptoms Worsening of associated conditions Any new PAH-related symptoms BMP, basic metabolic panel 9
11 Medication Index What You Need to Know About Pulmonary Arterial Hypertension The following medications were discussed in this presentation. The table below lists the generic and trade name(s) of these medications. Generic Name Ambrisentan Azithromycin Bosentan Gemfibrozil Levofloxacin Macitentan Riociguat Selexipag Sildenafil Sublingual Nitroglycerin Trade Name Letairis Zithromax, Zmax Tracleer Lopid Levaquin Opsumit Adempas Uptravi Revatio Gonitro, Nitrolingual Pumpspray, Nitromist, Nitrostat
12 Notes
13
ACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care physicians who can contribute to early detection of disease and who are responsible
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationThe COPD-PH Consult. When to Consider Pulmonary Vascular Disease. Diagnostic Algorithm for Pulmonary Hypertension
The COPD-PH Consult 52-year-old white male with COPD, HTN, presents with progressive DOE Current Meds: LABA/LAMA 5 years ACEI year 2 exacerbations in last year 2 LPM oxygen 6 mo An echo is ordered Function
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Hypertension A-Z
Pulmonary Hypertension A-Z Lana Melendres-Groves UNM Pulmonary Hypertension Program Director Assistant Professor of Medicine Pulmonary/Critical Care Division 9/17/16 Disclosures Advisory board member Actelion
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.23 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: September 15, 2017 Sildenafil
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care providers who can contribute to early detection of disease and who are responsible
More informationNavigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines
Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines Host: Marc Humbert Speaker: Simon Gibbs Marc HUMBERT, MD, PhD Professor of Respiratory
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationRight Ventricular Failure and Pulmonary Hypertension 2011
Right Ventricular Failure and Pulmonary Hypertension 2011 George G. Sokos, DO FACC Assistant Professor of Medicine, Temple University Director, Advanced Heart Failure and Cardiac Transplant Fellowship
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationREVATIO (sildenafil)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationUpdate on pulmonary HTN
Update on pulmonary HTN Feras Bader, MD, MS, FACC Associate Professor of Medicine- Cardiology University of Utah School of Medicine Director, Advanced Heart Failure and Transplant Program Dabbous Cardiac
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More information2/4/2011. Nathan Kerner, M.D.
Nathan Kerner, M.D. Definition Elevated pressures - cut off usually >40 mmhg pulmonary artery systolic pressure (PASP) Usually associated with elevated pulmonary vascular resistance (PVR) measured in dynessec/cm
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder
RATIONALE FOR INCLUSION IN PA PROGRAM Background Sildenafil and Tadalafil are marketed as Revatio and Adcirca for pulmonary arterial hypertension. This is a rare disorder of the pulmonary arteries in which
More informationEmerging Challenges in Primary Care: Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Emerging Challenges in Primary Care: 2018 Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice 1 Alexander Duarte, MD Professor Division of Pulmonary Critical
More informationPULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER
PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDisclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension Susan P. D Anna MSN, APN-BC, CHFN June 24, 2016 Disclosures Objectives Differentiate structure and function of RV and LV
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More information2nd ECHO ASE-ASEAN: Bangkok 22nd October DR. TAN JU LE Pulmonary Hypertension Services National Heart Centre SINGAPORE
2nd ECHO ASE-ASEAN: Bangkok 22nd October 2016 DR. TAN JU LE Pulmonary Hypertension Services National Heart Centre SINGAPORE Definition of Pulmonary Hypertension and Cor Pulmonale Epidemiology and Pathophysiology
More informationInstructions: This form is completed and entered for all participants. Database will skip over sections that do not apply.
Revision of 08/30/2017 Form #102 Page 1 of 6 PVDOMICS STUDY PVD Assessment - Form #102 Instructions: This form is completed and entered for all participants. Database will skip over sections that do not
More informationCase Presentation : Pulmonary Hypertension: Diagnosis and Imaging
Case Presentation 9.40-11.20: Pulmonary Hypertension: Diagnosis and Imaging Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflicts of interest Consulting fees and fees for
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More information5/2/18. Emerging Challenges in Primary Care: Faculty. Disclosures
Emerging Challenges in Primary Care: 2018 Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice Faculty Alexander Duarte, MD Professor Division of Pulmonary
More informationEmerging Challenges in Primary Care: Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Emerging Challenges in Primary Care: 2018 Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice Faculty Alexander Duarte, MD Professor Division of Pulmonary
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationDisclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
Disclosures A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension No financial relationships Susan P. D Anna MSN, APN BC, CHFN September 29, 2016 Objectives RV vs LV Differentiate
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationDr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham
Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Types of Questions you Will Be Asked Rhetorical Participatory Disclosure of Relevant Financial
More informationAcute Right Ventricular Failure
Acute Right Ventricular Failure Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy, and Medical Director Center for Thrombosis und Hemostasis, University of Mainz,
More informationPulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes
Pulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes Hap Farber, MD Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures Consultant:
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationObjectives. Disclosure. Objectives. Treatment of Pulmonary Hypertension 3/4/2016. Pharmacist Objectives: 3. Technician Objectives:
Objectives Treatment of Pulmonary Hypertension Janet Job PGY-1 Pharmacy Practice Resident Memorial Regional Hospital March 12, 2016 Pharmacist Objectives: Identify the pathophysiology, clinical presentation,
More information6/19/18. Emerging Challenges in Primary Care: Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Emerging Challenges in Primary Care: 2018 Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice 1 Alexander Duarte, MD Professor Division of Pulmonary Critical
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationPulmonary-Vascular Disease. Howard J. Sachs, MD.
Pulmonary-Vascular Disease Howard J. Sachs, MD www.12daysinmarch.com Dyspnea Cardiac Pulmonary CAD Pump Failure Chest Wall Airways Valve Disease Pericardial Disease Alveoli Interstitium Rhythm Disturbance
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationFiltering through the Facts: Portopulmonary Hypertension Saturday, September 19, :15 10:05 a.m.
Filtering through the Facts: Portopulmonary Hypertension Saturday, September 19, 2015 9:15 10:05 a.m. Joel Wirth, MD Pulmonary & Critical Care Medicine Maine Medical Center, Portland, ME Disclosures Dr.
More informationScleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas
Scleroderma and PAH Overview PH Resource Network 2007 Martha Kingman, FNP C UTSW Medical Center at Dallas Scleroderma and PAH Outline: Lung involvement in scleroderma Evaluation of the scleroderma patient
More informationCor pulmonale. Dr hamid reza javadi
1 Cor pulmonale Dr hamid reza javadi 2 Definition Cor pulmonale ;pulmonary heart disease; is defined as dilation and hypertrophy of the right ventricle (RV) in response to diseases of the pulmonary vasculature
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationDisclosure. RV is not the innocent bystander 10/1/16. Assessment and Management of Pulmonary Heart Disease in the Female Patient
Assessment and Management of Pulmonary Heart Disease in the Female Patient Oct 1, 2016 Deborah Women s Heart Center Susan E Wiegers, MD, FASE, FACC Professor of Medicine Senior Associate Dean of Faculty
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationSildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate
More informationPulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander
Pulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander Jacqueline Fearon-Clarke, MA, ACNP-BC Heart Failure and Pulmonary Hypertension Nurse Practitioner
More informationA Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider. Disclosures
A Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider Sean M. Studer, MD, MSc Chief, Pulmonary & Critical Care Director, Pulmonary Hypertension & Lung Transplantation
More informationPulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Deedre Boekweg RN, BSN, CCRP Intermountain Medical Center Murray, UT Kerri Akaya Smith, MD University of Pennsylvania Philadelphia, PA PHPN
More informationSA XXXX Special Authority for Subsidy
SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationPulmonary Hypertension: ICD-10 I27.0, I27.2
Dr Manish Barman, MD. Membership and Affiliations ESC, European association of cardiovascular prevention and rehabilitation. Acute Cardiovascular Care Association. ESC, Working Group on Hypertension &
More informationPrior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function. Irmina Gradus-Pizlo, MD
Pulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function Irmina Gradus-Pizlo, MD Disclosures: Nothing to disclose Overview Is pulmonary hypertension
More informationRecogni(on & Evalua(on of the Pa(ent with PAH: The need for early diagnosis
Recogni(on & Evalua(on of the Pa(ent with PAH: The need for early diagnosis James R. Klinger, MD Division of Pulmonary Medicine Rhode Island Hospital Professor of Medicine Alpert Medical School of Brown
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationClinical implication of exercise pulmonary hypertension: when should we measure it?
Clinical implication of exercise pulmonary hypertension: when should we measure it? Jang-Young, Kim Wonju College of Medicine, Yonsei Univ. Exercise pulmonary hypertension (EPH) Introduction of pulmonary
More informationThe US REVEAL Registry
Pulmonary Hypertension: Lessons from Contemporary Registries The US REVEAL Registry ESC August 30, 2010 Dave Badesch, MD University of Colorado Disclosures Dr. Badesch has received grant/research support
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More information5 consecutive cases of PH I wish I never saw
5 consecutive cases of PH I wish I never saw Abubakr A Bajwa. MD, FCCP Associate Professor of Medicine Division Chief Pulmonary, Critical Care and Sleep Medicine Director Pulmonary Hypertension and Interstitial
More information